Compass Pathways will be testing the active ingredient of magic mushrooms, psylocybin, as a treatment for depression.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Compass Pathways or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.